SecBot SecBot
6-K ·Filed Aug 31, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 7/10
Horizonimmediate Processed2mo ago SEC0001648257-26-000055
Notable filing: 6-K
Actionable Insight ▲ Bullish

Expect positive stock reaction on this first-line Phase III win. Monitor for regulatory submission in China and potential label expansion.

DirectionBullish
Confidencehigh
Horizonimmediate

Drug in focus

HCM drug pipeline →

ORPATHYS

◆ Mixed Named in this 6-K
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$12.12
T+0 close · Aug 31, 2026 · via day close
Latest settled
+16.75%
T+20 · $14.15 · next T+60 in 7d
Vs SPY
+16.94%
α at T+20
Latest observation
+20.49%
T+52 · FF3 residual α
  1. T+0 · Aug 31 $12.12entry
  2. T+1 · 3mo ago −1.73%α −1.05% · $11.91
  3. T+5 · 2mo ago +14.52%α +14.66% · $13.88
  4. T+20 · 7w ago +16.75%α +16.94% · $14.15
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) significantly improves progression-free survival vs TAGRISSO alone in first-line MET-overexpressing EGFR-mutated NSCLC in China. The combination also demonstrated encouraging overall survival benefit. This expands the clinical value of the all-oral combination into the first-line setting, building on prior SACHI and SAFFRON trials. The data will be submitted to regulatory authorities for label expansion in China.

Key Facts

  • SANOVO Phase III met primary endpoint: statistically significant and clinically meaningful PFS improvement vs TAGRISSO alone in both high MET and ITT populations
  • Encouraging OS benefit observed as secondary endpoint; trial continues follow-up
  • Safety profile consistent with known profiles of each medicine; no new safety findings
  • 326 treatment-naïve patients randomized 1:1 to ORPATHYS+TAGRISSO vs TAGRISSO+placebo
  • ORPATHYS jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca
  • ORPATHYS+TAGRISSO already approved in China for later-line MET-amplified EGFR-mutated NSCLC based on SACHI trial

Financial Impact

Potential label expansion into first-line NSCLC in China significantly expands addressable patient population for ORPATHYS+TAGRISSO combination; no specific revenue figures provided in filing

revenuepipeline value

Risk Factors

  • Regulatory approval for first-line indication not guaranteed; data review timeline uncertain
  • Competition from other MET-targeted therapies and EGFR-TKI combinations
  • OS data immature; final OS readout may differ from interim encouraging trend

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000055
Document: hcm-20260831x6k.htm0001648257-26-000055
Document: 0001648257-26-000055-index-headers.html0001648257-26-000055
Document: 0001648257-26-000055-index.html0001648257-26-000055
Document: 0001648257-26-000055.txt0001648257-26-000055

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026